Apyx Medical files Q2 2026 earnings update
Apyx Medical Corporation reported that on August 6, 2026 it issued a press release presenting its results of operations for the second quarter ended June 30, 2026.
Rhea-AI Filing Summary
Apyx Medical Corporation reported that on August 6, 2026 it issued a press release presenting its results of operations for the second quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and is incorporated by reference.
The company states that this earnings information is furnished under Item 2.02 of the Exchange Act, rather than filed for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act reports unless specifically referenced. The report also identifies a Cover Page Interactive Data File, prepared using Inline XBRL, as Exhibit 104.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Earnings press release date: August 6, 2026
Reporting period end date: June 30, 2026
Exhibit 99.1: 99.1
+1 more
4 metrics
Earnings press release date
August 6, 2026
Date Apyx Medical issued the press release on results of operations
Reporting period end date
June 30, 2026
Second quarter ended June 30, 2026 covered by the earnings press release
Exhibit 99.1
99.1
Earnings press release dated August 6, 2026 attached as Exhibit 99.1
Exhibit 104
104
Cover Page Interactive Data File identified as Exhibit 104
Key Terms
Results of Operations and Financial Condition, Inline XBRL, Section 18 of the Securities Exchange Act of 1934, emerging growth company
4 terms
Results of Operations and Financial Condition financial
"Item 2.02 Results of Operations and Financial Condition On August 6, 2026"
Inline XBRL technical
"104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Section 18 of the Securities Exchange Act of 1934 regulatory
"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Earnings Snapshot
second quarter ended June 30, 2026
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Apyx Medical (APYX) disclose in its August 6, 2026 Form 8-K?
Apyx Medical disclosed that it issued a press release on August 6, 2026 covering its results of operations for the second quarter ended June 30, 2026. The press release is attached as Exhibit 99.1 and incorporated by reference.
Which period do Apyx Medical’s (APYX) latest reported results cover?
The results discussed by Apyx Medical cover the second quarter ended June 30, 2026. That period is the focus of the earnings press release furnished as Exhibit 99.1 to the Form 8-K.
How is Apyx Medical’s (APYX) Q2 2026 earnings information treated for SEC purposes?
The Q2 2026 earnings information is described as furnished under Item 2.02, not filed under Section 18 of the Exchange Act. It is not automatically incorporated into other Securities Act or Exchange Act reports unless specifically referenced.
What exhibits are included with Apyx Medical’s (APYX) August 6, 2026 Form 8-K?
The Form 8-K lists two exhibits: Exhibit 99.1, the earnings press release dated August 6, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.
Who signed Apyx Medical’s (APYX) August 6, 2026 Form 8-K?
The report was signed on behalf of Apyx Medical by Matthew Hill, who serves as Chief Financial Officer, Secretary and Treasurer. His signature appears on the Form 8-K dated August 6, 2026.
Does Apyx Medical (APYX) identify itself as an emerging growth company in this report?
The cover information references the emerging growth company designation under Rule 12b-2 of the Exchange Act. This indicates the company is evaluating or using that classification as part of its disclosure framework.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices, zip code)
(727 ) 384-2323
(Issuer's telephone number)
_____________________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition
On August 6, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the second quarter ended June 30, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
This information is intended to be furnished under Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
Earnings press release dated August 6, 2026
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: August 6, 2026
|
Apyx Medical Corporation
|
||
|
By:
|
/s/ Matthew Hill
|
||
|
Matthew Hill
|
|||
|
Chief Financial Officer, Secretary and Treasurer
|
|||